April 24th 2024
Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Eye on Pharma: Alternatives to Blockbuster Ophthalmology, Diabetes Meds Progress
April 14th 2022Access to new treatment options for ophthalmic conditions and diabetes is on the rise with the launch of Sandoz’ generic ocular hypertension medication, a new deal to bring a ranibizumab biosimilar to the Middle East, and the initiation of a trial for an insulin glargine biosimilar.
Cardinal Health Report Sees 2022 as “Turning Point” for Biosimilars
February 8th 2022The year 2022 “is set to be a turning point” in the United States, as biosimilars are on their way to delivering $133 billion in aggregate savings by 2025, according to Cardinal Health's “2022 Biosimilars Report: The U.S. Journey and Path Ahead.”
What's Holding Up Biosimilar Uptake? Misconceptions, Misaligned Incentives, Panelists Say
January 26th 2022US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.